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http://dx.doi.org/10.1016/j.ccr.2012.12.003Open access under CC BY-NC-ND license.SUMMARYTumor cell survival critically depends on heterotypic communication with benign cells in the microenviron-
ment. Here, we describe a survival signaling pathway activated in stromal cells by contact to B cells from
patients with chronic lymphocytic leukemia (CLL). The expression of protein kinase C (PKC)-bII and the
subsequent activation of NF-kB in bone marrow stromal cells are prerequisites to support the survival of
malignant B cells. PKC-b knockout mice are insusceptible to CLL transplantations, underscoring the in vivo
significance of the PKC-bII-NF-kB signaling pathway in the tumor microenvironment. Upregulated stromal
PKC-bII in biopsies from patients with CLL, acute lymphoblastic leukemia, and mantle cell lymphoma
suggests that this pathway may commonly be activated in a variety of hematological malignancies.INTRODUCTION
Chronic lymphocytic leukemia (CLL) is one of the most common
B cell malignancies in adults, characterized by an accumulation
of monoclonal CD5+ mature B cells in lymphoid tissues and
the peripheral blood. The deletion of chromosome 13q14.3 re-
presents the most common genetic alteration in CLL, causing
autonomous B cell proliferation by affecting the expression ofSignificance
Tumor-host interactions are crucial for the survival and progre
environment may therefore constitute an alternative to cytotox
the tumor microenvironment is induced by malignant cells fr
required for the activation of NF-kB in bone marrow stromal
the survival of CLL cells in vitro and in vivo, demonstrating
pathway activated in the tumor microenvironment may be a mthe microRNA cluster 15a/16-1 (Do¨hner et al., 2000; Klein
et al., 2010). Whole-genome sequencing recently identified
recurrent mutations in NOTCH1, MYD88, and SF3B1 in CLL,
opening up insights in the mechanisms of clonal evolution
(Fabbri et al., 2011; Puente et al., 2011; Quesada et al., 2012;
Wang et al., 2011). Increased expression levels of antiapoptotic
proteins have reinforced the hypothesis that a cell intrinsic defect
of apoptosis is causative for B cell longevity and a steadyssion of cancer cells. Specific targeting of the tumor micro-
ic therapies. Here, we show that the expression of PKC-bII in
om patients with CLL, ALL, and mantle cell lymphoma and
cells. Interference with PKC-bII induction critically impairs
that therapeutic targeting of the PKC-bII-NF-kB signaling
eaningful treatment option.
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Figure 1. Stromal Cells Reminiscent of CAFs Support the Survival of CLL Cells
(A) Malignant B cells from patients with CLL, or CD19+ or CD5+ B cells from healthy individuals, were cultured on the stromal cell line EL08-1D2 for 5 days before
analyzing apoptotic cells by Annexin-V/PI staining.
(B) Cell-free supernatants from EL08-1D2 cells or from cocultures with CLL after 5 days were analyzed using amouse cytokine antibody array. Results from three
individual experiments with different primary CLL cells were quantified using ImageJ software. Fold induction is defined as compared to cytokine levels detected
in an EL08-1D2 monoculture. Error bars show mean ± SEM. Significantly upregulated cytokines upon CLL contact are marked by red boxes.
(legend continued on next page)
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et al., 2005; Kitada et al., 1998). However, primary CLL cells
rapidly die ex vivo despite high levels of Bcl2 but can be cultured
for weeks in the presence of different types of stromal cells
(Burger et al., 2000; Ding et al., 2009; Pedersen et al., 2002).
This indicates that the apoptosis defect in CLL is not cell auton-
omous but highly dependent on extrinsic signals derived from
their microenvironment. Notably, this is not a static interaction
in which stromal cells constitutively provide prosurvival signals
to malignant cells but a dynamic process driven by bidirec-
tional communications between the two. In the present study,
we sought to investigate how CLL cells activate bone marrow
stromal cells (BMSCs) and to characterize the signaling path-
ways and their functional consequences underlying this cell-
cell communication.
RESULTS
Stromal Cells Reminiscent of Cancer-Associated
Fibroblasts Support the Survival of Malignant B Cells
Derived from Patients with CLL
To study heterotypic cell-cell communications between stromal
and CLL cells, we established a coculture system using primary
leukemic B cells derived from patients’ blood and the murine cell
line EL08-1D2 (Figure S1A available online), which has been
carefully characterized as a stromal cell line able to maintain
hematopoietic progenitor and stem cells ex vivo (Oostendorp
et al., 2002). Analysis of apoptotic CLL cells after 5 days of
coculture demonstrated that they were protected from sponta-
neous apoptosis. This antiapoptotic effect of stromal cells could
not be recapitulated with CD19+ peripheral blood B cells.
Notably, stromal cells provided little protection from sponta-
neous apoptosis of CD5+ B1 cells derived from blood of healthy
donors (Figures 1A and S1B).
To define cytokines induced in CLL-stroma cocultures, super-
natants from these cocultures were analyzed using a mouse-
cytokine antibody array. Of the 62 cytokines measured in this
assay, 6 were significantly upregulated in CLL-stroma cocul-
tures: SDF-1a, IL-6, G-CSF, GM-CSF, MIP-3a, and CXCL16
(Figure 1B). Because all the antibodies used in this analysis,
with the exception of anti-SDF-1a, were specific to mouse cyto-
kines, the detected cytokines must have been produced by the
murine stroma and not the human CLL cells. The consistent
upregulation of proinflammatory cytokines by stromal cells in
response to contact with leukemic B cells suggested that
EL08-1D2 cells share properties akin to so-called cancer-asso-
ciated fibroblasts (CAFs).
CAFs are characterized by promoting growth and invasion of
epithelial tumors (Kalluri and Zeisberg, 2006), but their role in
the pathogenesis of CLL is less clear. Immunofluorescence of
EL08-1D2 cells demonstrated that a-SMA and stress fibers,(C) Immunofluorescent staining for a-SMA (a and b), stress fibers (c and d, indicate
(e and f) in EL08-1D2 cells. CLL cells were removed from cocultures before fixat
(D) Gene expression profiles of EL08-1D2 cells without and after 5 days’ cont
ontologies exhibiting significant overrepresentation in the target list derived from
genes are given. The *CAF panel shows significantly upregulated genes in CAFs
patient IDs.
See also Figure S1 and Tables S1 and S2.both of which have been used to identify CAFs (Kalluri and
Zeisberg, 2006; Tlsty and Coussens, 2006), were induced by
contact with CLL cells (Figure 1C, a–d). This remodeling of the
actin skeleton depends on the GTP-binding protein RhoA (Ridley
and Hall, 1992). Correlating with the formation of stress fibers,
RhoA was expressed in EL08-1D2 cells upon CLL contact (Fig-
ure 1C, e and f).
For further characterization of EL08-1D2 cells, we compared
transcriptomes of EL08-1D2 cells before and after 5 days of
contact with CLL cells, derived from multiple donors. We found
474 genes consistently increased (Table S1) and 347 decreased
(Table S2) in stromal cells, of which 129 and 40 genes showed
greater than 2-fold change, respectively. Subjecting these 821
consistently altered target probe sets to overrepresentation
analysis using GeneTrail (http://genetrail.bioinf.uni-sb.de/index.
php) revealed significant enrichments for the gene ontology
terms ‘‘inflammatory response’’ (p = 6.0 3 105) and ‘‘response
to wounding’’ (p = 7.2 3 109) (Figure 1D). It was recently re-
ported that CAFs from skin, mammary, and pancreatic tumors
in mice are characterized by a proinflammatory gene signature
(Erez et al., 2010). Comparison of those genes to our results re-
vealed significant overlap of target genes (Figure 1D, lower
panel). Therefore, in coculture, EL08-1D2 cells support the
survival of malignant B cells and undergo genetic and morpho-
logic alterations reminiscent of CAFs.
CLL Cells Induce the Expression of Stromal PKC-bII
Interactions between fibroblasts and tumor cells can contribute
to drug resistance by increasing the expression of antiapoptotic
proteins in tumor cells (Meads et al., 2009). We previously re-
ported that the intrinsic activation of protein kinase C (PKC)-bII
in CLL cells mediates apoptosis resistance due to posttransla-
tional modifications of Bcl2 and BimEL (zum Bu¨schenfelde
et al., 2010). Therefore, we tested whether the PKC-b inhibitor
enzastaurin could overcome the protective effect of EL08-1D2
cells on CLL cells. CLL cells cultured on EL08-1D2 cells were
not protected from the cytotoxic effect of enzastaurin, whereas
the cytotoxicity of doxorubicin was mitigated by contact with
stromal cells (Figure 2A). Importantly, neither enzastaurin nor
doxorubicin significantly influenced the viability of EL08-1D2
cells (Figure S2A). These data imply that PKC-b plays an impor-
tant role in stroma-CLL interactions. To further analyze this
effect, we assessed the expression of classical PKC isoforms
in either cell compartment before and after coculture. CLL cells
predominantly express PKC-bII (Abrams et al., 2007), but its level
of expression was unmodified after contact with EL08-1D2 cells
(Figure 2B). In contrast, PKC-bII was not constitutively ex-
pressed in EL08-1D2 cells. However, contact with several
different primary leukemic B cells induced the expression of
PKC-bII in EL08-1D2 cells, but not PKC-a or PKC-bI, that were
constitutively expressed in EL08-1D2 cells. The absence ofd by the organization of actin bundles, stained by using a-phalloidin), and RhoA
ion and staining the sections with antibodies.
act with CLL cells were compared. Heatmaps show the expression of gene
the microarray experiment. All probe sets interrogating the respective target
from dysplastic skin tissue (Erez et al., 2010). ‘‘V’’ numbers indicate encrypted
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Figure 2. Enhanced Survival of CLL Cells Is Associated with Induction of PKC-b in Stromal Cells
(A) CLL cells in media or after 5 days of coculture with EL08-1D2 cells were exposed to enzastaurin or doxorubicin for 48 hr. Apoptotic leukemic cells were
detected by Annexin-V/PI staining. Error bars show mean ± SEM from eight (medium) and five (cocultures) individual experiments. ***p < 0.001, **p < 0.01,
*p < 0.05; ns, statistically nonsignificant.
(B) CLL and EL08-1D2 cells were separated after 5 days’ coculture. Expression of classical PKC isoforms was analyzed in each cell compartment.
One representative western blot out of three individual experiments with different CLL samples is shown.
(legend continued on next page)
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a ZAP70-positive CLL demonstrated that CLL contamination of
stromal cell lysates is negligible in these experiments (Figures
2B and S2B). Of note, normal peripheral blood B cells from
healthy donors did not induce PKC-bII in stromal cells
(Figure 2C).
Subcellular fractioning of stromal cell proteins before and after
CLL contact indicated that induced PKC-bII was located in the
cytoplasm, but not the nucleus (Figure 2D). Quantitative RT-
PCR using mouse-specific primers showed that upregulation
of PKC-b in EL08-1D2 cells was mostly due to transcriptional
regulation (Figure 2E). To further exclude the possibility of
cross-contamination with PKC-bII-positive CLL cells, we
assessed PKC-bII expression in stromal cells by immunofluores-
cence. After 5 days of coculturing CLL cells on EL08-1D2 cells,
CLL cells were removed and stromal cells analyzed for the
expression of PKC-bII. Stromal cells could be identified by
a positive staining for Sca-1 (Oostendorp et al., 2002), which is
not expressed on CLL cells. Stromal PKC-bII was detected
with a perinuclear expression pattern, characteristic of activated
PKC-bII (Becker and Hannun, 2003) (Figure S2C, a–d and i).
PKC-bII could not be detected in EL08-1D2 monocultures (Fig-
ure S2C, e–h). We next examined whether a direct contact
between CLL cells and stromal cells was required to protect
CLL cells from apoptosis and to induce the expression of
PKC-bII in EL08-1D2 cells, and we found that both were lost if
these cell compartments were separated in a transwell experi-
ment (Figures 2F and 2G). Furthermore, conditioned medium
from EL08-1D2/CLL cocultures failed to support survival of
leukemic cells (Figure S2D).
To eliminate the concern that the results seen so far were
limited to coculturing human leukemic B cells on a murine cell
line, we cocultured primary human CLL cells on primary human
BMSCs (hBMSCs). Similar to EL08-1D2 cells, hBMSCs sup-
ported ex vivo survival of CLL cells, and accordingly, PKC-bII
was induced (Figures 2H and 2I). Irradiation of EL08-1D2 cells
or hBMSCs before coculturing abolished their antiapoptotic
effect on CLL cells, indicating that only signaling competent
stromal cells can protect CLL cells from cell death (Figure S2E).
hBMSCs are a heterogeneous mixture of different cell types.
To further define the subsets of cells that were responsible for
these effects, we cocultured CLL cells on human umbilical
vascular endothelial cells (HUVECs), primary human osteoblasts
(hObs), and a murine osteoblast-cell line (MC3T3) under compa-
rable conditions as used for EL08-1D2/CLL cocultures. Remark-(C) Expression of PKC-bII in EL08-1D2 cells after coculture with normal CD19+ B
(D) PKC-bII in the cytoplasmic (C) or nuclear (N) fraction of EL08-1D2 cells after
experiment out of four is shown.
(E) Quantitative RT-PCR using mouse-specific primers for PKC-b and PKC-a in
contact was normalized to the expression of actin and compared to the expression
by the Pfaffl formula based on mean Ct values ±SEM from five experiments. ****
(F and G) CLL cells and EL08-1D2 were directly cocultured or separated by a tran
(F), and PKC-bII expression was assessed by western blotting (G). One represen
(H) CLL cells were cocultured with primary hBMSCs (n = 5), HUVECs (n = 4), hObs
bars show mean ± SEM.
(I) Induction of PKC-bII in primary hBMSCs following 5 days of coculturing with t
(J) PKC-bII expression in HUVECs and osteoblasts detected by immunoblotting
(K) PKC-bII expression in primary hBMSCs after coculturing with CLL cells at ind
See also Figure S2.ably, all cell types supported CLL survival (Figure 2H), accom-
panied by PKC-bII induction (Figure 2J). Finally, extended
cocultures of CLL cells and hBMSCs for 4 weeks demonstrated
that stromal PKC-bII induction was not transient but persistent
(Figure 2K).
Induction of Stromal PKC-b Is Required for Stromal
Cell-Mediated Protection of CLL Cells
The strong correlation between PKC-bII upregulation and
survival of CLL cells suggested that stromal PKC-bII was impor-
tant for the antiapoptotic signals provided by EL08-1D2 cells. To
test this hypothesis, PKC-bII induction in EL08-1D2 cells was
suppressed using a siRNA directed against stromal PKC-bII.
siRNA transfection of EL08-1D2 was performed 24 hr before
coculturing with CLL cells to ensure that the PKC-bII of CLL cells
was not targeted. PKC-a and PKC-b expression in EL08-1D2
cells was assessed by immunoblotting after 5 days of cocultur-
ing with CLL cells and showed that only PKC-bII was effectively
targeted (Figure 3A). Analyzing the viability of CLL cells cultured
on EL08-1D2 cells proficient or depleted of PKC-bII indicated
that stromal PKC-bII was required for the survival of CLL cells
(Figure 3B). Knockdown of stromal PKC-bII significantly
impaired the survival of all samples tested from individual
patients with CLL. This was particularly relevant because CLL
is a heterogeneous disease with variations in the clinical course.
The aberrant expression of ZAP70 in monoclonal B cells can be
used as a prognostic marker of a more aggressive variant of CLL
(Crespo et al., 2003). However, PKC-bII knockdown in stromal
cells affected the survival of ZAP70-positive and -negative
CLL, similarly (Figure 3C).
To eliminate the possibility that off-target effects of the PKC-
bII siRNA accounted for the impaired survival of CLL cells, we
recapitulated our experiments with primary BMSCs from wild-
type and PKC-b knockout (Prkcb/) mice. Prkcb/ mice,
which lack both bI and bII isoforms, are characterized by an
impaired immune response but have no overt phenotype in
the bone marrow stromal compartment (Leitges et al., 1996).
CLL cells were effectively protected from spontaneous
apoptosis when cocultured on wild-type BMSCs, accompanied
by induction of PKC-b in stromal cells (Figures 3D and S3A).
This protection effect was significantly impaired on Prkcb/
stromal cells (Figures 3D and 3E). Characterization of the
primary CLL cells used in these experiments, based on stan-
dard cytogenetic analyses and sequencing of TP53 (exons
4–11) and NOTCH (exons 25–34), did not identify any subsetcells or CLL.
contact with CLL cells is detected using immunoblotting. One representative
EL08-1D2 cells. The relative induction of the expression of each gene by CLL
in EL08-1D2monocultures (depicted as fold induction). Results are calculated
p < 0.0001.
swell. After 5 days, apoptotic CLL cells were detected by Annexin-V/PI staining
tative experiment out of three is shown.
(n = 3), andMC3T3 (n = 3) for 5 days before analyzing apoptotic CLL cells. Error
wo primary CLLs. ZAP70-positive CLL cells were used as positive controls.
at the end of the coculture experiment.
icated time points.
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Figure 3. Induction of PKC-bII in Stromal Cells Is Crucial for Apoptosis Protection of CLL Cells
(A) EL08-1D2 cells were transfected with siRNA directed against PKC-bII or a control siRNA. Twenty-four hours after transfection, CLL cells were cocultured on
EL08-1D2 cells for 5 days. PKC-bII expression was assessed by immunoblotting performed from cell lysates of EL08-1D2 cells at the end of the coculture (n = 4
individual experiments, using different CLL samples).
(B) Survival of CLL on EL08-1D2 cells, transfected with siRNAs as indicated, was assessed by Annexin-V/PI staining of leukemic B cells after 5 days (n = 20).
****p < 0.0001.
(C) Data from (B) were analyzed based on ZAP70 expression of CLL cells (n = 7 for ZAP70 positive and n = 8 for negative samples).
(D and E) Survival of CLL cells on primary BMSCs from four individualPrkcb/ or wild-typemice. Viability was assessed by a negative Annexin-V/PI staining (D) or
by trypan blue exclusion (E). Patient IDs were encrypted using V and P numbers. The following patient samples were cocultures on BMSCs from Prkcb/:
animal 1, V261, V128, and P12; animal 2, V172 and P26; animal 3, V231, V253, and V194; and animal 4, V270 and V131. ***p < 0.001, **p < 0.01.
(F) Ten individual CLL samples were cultured in medium or cocultured on BMSCs from wild-type or Prkcb/ animals for 5 days. Wild-type PKC-b or a kinase-
dead mutant of PKC-b (K371R) was ectopically expressed in Prkcb/ BMSCs as indicated. Apoptotic CLL cells were analyzed by Annexin-V/PI staining after
5 days’ coculture.
(legend continued on next page)
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than others (Table S3).
Ectopic expression of the wild-type PKC-b in Prkcb/
BMSCs rescued their ability to provide survival cues to CLL cells
(Figure 3F), confirming that PKC-b expressed in stromal cells is
required for the survival of CLL cells. Moreover, expression of
a kinase-dead mutant (K371R) of PKC-b (Feng and Hannun,
1998) failed to restore the survival functions of Prkcb/ BMSCs,
indicating that the kinase activity of PKC-b is essential for
stroma-mediated protection of CLL cells fromapoptosis (Figures
3F and S3B). The uniform upregulation of PKC-bII (Figures 2I
and 2J) suggested that the antiapoptotic effect of different
types of stromal cells on CLL cells was attributed to its ex-
pression. Consistent with this hypothesis, knockdown of PKC-
bII in HUVECs abolished their prosurvival effects on CLL cells
(Figure 3G).
PKC-bII Activates Stromal NF-kB through the Canonical
Pathway
PKC-b connects the B cell receptor to canonical activation of
NF-kB through a signaling complex, including Bcl10/MALT1
and NEMO/IKKg (Zhou et al., 2004). Because stromal cells
activated by CLL cells showed a proinflammatory phenotype
(Figure 1), we investigated whether NF-kB activation could
also occur following induction of PKC-bII in stromal cells and
found that activation of NF-kB occurred in wild-type, but not in
Prkcb/ BMSCs in response to CLL contact (Figure 4A). These
results were recapitulated in EL08-1D2 cells and in hBMSCs
(Figures 4B and S4A).
To test whether the loss of NF-kB activation was primarily
dependent on PKC-b expression or a secondary event based
on the impaired survival of CLL cells on PKC-b-deficient stromal
cells, apoptosis of CLL cells was inhibited using the caspase
inhibitor z.vad.fmk. Caspase inhibition rescued CLL cells cul-
tured on PKC-b-deficient stromal cells from spontaneous
apoptosis but did not result in activation of NF-kB in PKC-
b-deficient stromal cells (Figures S4B and S4C), suggesting
that PKC-b is directly involved in the activation of NF-kB. This
activation is regulated by nuclear translocation and DNA binding
of NF-kB subunits (Hayden and Ghosh, 2004). Fractionation of
EL08-1D2 cell lysates showed that the NF-kB subunits p50,
p65, and c-REL accumulated in the nucleus upon contact with
monoclonal B cells (Figures 4C and S4D).
To further elaborate whether Bcl10 was linking PKC-bII to
NF-kB activation in stromal cells, we used BMSCs from
Bcl10/ and wild-type mice for coculture experiments. Primary
CLL cells survived equally well on Bcl10/ and wild-type
stromal cells (Figure 4D). Accordingly, CLL-dependent activation
of NF-kB was not inhibited in Bcl10/ stroma (Figure 4E).
Notably, stromal PKC-bII was induced uponCLL contact regard-
less of Bcl10 (Figure 4F), excluding Bcl10 as a critical protein for
PKC-bII-mediated activation of NF-kB in stroma cells.
To assess whether stromal NF-kB was important for the pro-
survival effects on malignant B cells, we analyzed the viability(G) Survival of CLL cells was assessed by Annexin-V/PI staining after 5 days of c
The experimental conditions were similar to the experiment depicted in (A). *p <
Error bars in the entire figure show mean ± SEM.
See also Figure S3 and Table S3.of CLL cells in cocultures with EL08-1D2 cells in the presence
of an IKK2 inhibitor (Ziegelbauer et al., 2005). IKK2 (IKKb) is
a member of the multiprotein IkB complex that also contains
IKK1 (IKKa) and the essential regulatory subunit NEMO.
Blockage of IKK2 significantly affected survival of CLL cells on
stromal cells without affecting the viability of EL08-1D2 cells
(Figures 4G and S2A). This impaired survival of CLL cells was
associated with a decreased activation of NF-kB in stromal cells
(Figure 4H). However, it was possible that the proapoptotic effect
of the IKK2 inhibitor was exclusively related to NF-kB inhibition in
CLL cells. To disentangle stroma from CLL-specific effects, we
used BMSCs derived from conditional Nemo-knockout mice
(NemoF) (Schmidt-Supprian et al., 2000) and as controls BMSCs
from YFP reporter mice (Srinivas et al., 2001).Nemowas ablated
from isolated monocultures of NemoF/F stromal cells by treat-
ment with Cre protein (HTNC) (Figure 4J) (Peitz et al., 2002).
NEMO-proficient and -deficient BMSCs were then propagated
in the absence of HTNC for additional two passages before
CLL cells were added. Activation of NF-kB in NEMO-deficient
BMSCs was inhibited after CLL contact (Figure 4I), although
PKC-bII was still induced (Figure 4J). These results indicated
that PKC-bII was operating upstream of NEMO/NF-kB in
BMSCs. Importantly, NEMO-deficient BMSCs failed to support
the survival of primary CLL cells (Figure 4K), similar to loss of
stromal PKC-bII (Figure 3). The slightly reduced induction of
PKC-bII in NEMO-deficient BMSCs compared to untreated
NemoF/F cells is most likely related to an impaired survival of
and therefore reduced ‘‘induction signal’’ by CLL cells on these
BMSCs (Figure 4J). These findings provide evidence that induc-
tion of PKC-bII in stromal cells precedes the activation of NF-kB
and that the PKC-bII/NF-kB pathway is required for stromal cell-
mediated survival of malignant B cells.
Stromal NF-kB Regulates the Expression of
Proinflammatory Cytokines Required for CLL Survival
Comparing the transcriptome of HTNC-treated and -untreated
NemoF/F murine bone marrow stroma cells (mBMSCs) after
5 days of coculturing with CLL revealed that 372 genes were
significantly increased (R2-fold) in NEMO-proficient BMSCs
(Table S4). Accordingly, 388 genes were downregulated
(%0.5-fold) in BMSCs expressing NEMO (Table S5). Notably,
BMSCs from NemoF/F mice were HTNC treated at least 8 days
before the coculture with CLL cells, making it unlikely that
changes in gene expression were merely related to the addition
of HTNC. Using the GeneTrail software and the KEGG database
to further analyze these genes, we identified a gene cluster of
‘‘cytokine and cytokine-receptors’’ (p = 0.029) and a cluster of
‘‘cell adhesion molecules’’ (p = 0.004), which were decreased
in NEMO-deficient mBMSCs (Figure 5A).
To validate the differential regulation of these genes, we
analyzed the levels of IL-1a and IL-15, both of which have
been described to support CLL survival in the absence of stromal
cells (de Totero et al., 2008; Jewell et al., 1995), in supernatants
from CLL and BMSC cocultures after 5 days. CLL contactoculture with HUVECs that were transfected with siRNAs as indicated (n = 10).
0.05.
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Figure 4. Stromal PKC-bII Is Essential for NF-kB Activation in BMSCs in Response to Contact with CLL Cells
(A) NF-kB activation was assessed by EMSA in primary mBMSCs from wild-type or Prkcb/ mice after 5 days of coculturing with CLL cells. One out of three
experiments is shown.
(B) Activation of NF-kB in EL08-1D2 cells, transfected with the indicated siRNAs, was analyzed by EMSA after 5 days of coculture with CLL.
(C) NF-kB subunits in cytosolic (C) and nuclear (N) fractions from EL08-1D2 cells after 5 days in contact with CLL cells were detected by immunoblotting.
Ns. band, nonspecific band. One out of four experiments with different primary CLL cells is shown.
(D–F) CLL cells were cocultured on BMSCs from wild-type or aged-matched Bcl10/ mice for 5 days. Apoptosis of CLL cells was determined by Annexin-V
staining (D, n = 10). NF-kB activity was measured by EMSA (E), and PKC-bII expression was determined by immunoblotting (F). ***p < 0.001.
(G and H) Cocultures of CLL cells and EL08-1D2 cells were exposed to an IKK2 inhibitor for 5 days at the indicated concentrations. Apoptotic CLL cells were
analyzed by Annexin-V staining (G, n = 18), and NF-kB activation in EL08-1D2 cells was determined by EMSA (H). ****p < 0.0001, **p < 0.01, *p < 0.05.
(legend continued on next page)
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pletely abolished in NEMO-deficient BMSCs (Figure 5B). Similar
to IL-1a, IL-15 was induced in a NEMO-dependent manner in
stromal cells by CLL contact, although to greater variations (Fig-
ure 5C). Importantly, antibodies used in these ELISAs were
specific for murine IL-1a and IL-15 and not cross-reactive to
human cytokines, excluding the possibility that the detected
factors were produced by human CLL cells. Upregulation of
IL-1a and IL-15mRNA in hBMSCsuponCLLcontact (Figure S5A)
indicated that these results were not limited to xenogeneic
culture conditions.
Finally, to test that murine IL-1a, IL-1b, and IL-15 could rescue
primary CLL cells from apoptosis, increasing doses of these
cytokines were supplemented to CLL monocultures or CLL/
NEMO-deficient BMSC cocultures. The analysis of apoptotic
CLL cells after 5 days indicated that IL-1 and IL-15 partially
rescued NEMO deficiency in BMSCs (Figures 5D, 5E, and
S5B). Combining IL-1 and IL-15 demonstrated a stronger pro-
survival effect on CLL cells (Figure S5C). Notably, cytokine doses
required to partly compensate for NEMO deficiency in stromal
cells exceeded the concentrations of IL-1 and IL-15 produced
by stromal cells after CLL contact. This antiapoptotic effect
was reproducible in CLL monocultures, indicating that these
cytokines directly supported the survival of CLL cells through
a paracrine mechanism (Figures 5D, 5E, and S5B). Importantly,
mouse and human IL-1 and IL-15 are not entirely homologous
(IL-1a, 61%; IL-1b, 69%; and IL-15, 71%), and therefore, their
antiapoptotic effect may be underestimated in our experiment
compared to an in vivo scenario.
Stromal PKC-b Is Indispensable for the Engraftment
of TCL1/CLL In Vivo
Transgenic mice expressing TCL1 under the Em promotor
(TCL1tg) show a clonal expansion of CD5+ B cells and die of
a CLL-like disease (Bichi et al., 2002). About 40% of TCL1tg
mice develop a solid malignant tumor unrelated to the expres-
sion of TCL1, mostly soft tissue sarcomas (Zanesi et al., 2006).
To test the relevance of PKC-b in themicroenvironment for the
survival of monoclonal B cells in vivo, we transplanted splenic
cells from three individual lymphoma-bearing TCL1tg mice into
Prkcb/ or wild-type recipient mice. Because TCL1tg and
Prkcb/ mice were both backcrossed onto a C57BL/6 genetic
background, no immunosuppression was needed before trans-
plantation (Hofbauer et al., 2011). Tumor load was assessed
weekly by analyzing the amount of CD19+CD5+ B cells in the
peripheral blood of recipient mice. After 5 weeks, an increase
of CD19+CD5+ cells was detected in the blood of PKC-b wild-
type, but not of Prkcb/ recipient mice (Figure 6A). All wild-
type recipient mice died of a CLL-like disease after a mean of
59 days (range 48–84 days), whereas Prkcb/ recipient mice
stayed healthy and alive during that time (Figure 6B). We noticed(I and J) BMSCs from NemoF/Fmice were harvested, and Nemowas deleted by tr
additional two passages, cells were analyzed for their ability to activate NF-kB a
PKC-bII expression was assessed in mBMSCs at the end of the experiment (J).
(K) Survival of CLL cells onHTNC-treated and untreatedNemoF/FBMSCswas dete
from YFPF mice were used as controls.
Error bars in the entire figure show mean ± SEM.
See also Figure S4.that some of the Prkcb/ recipient mice, all of which were trans-
planted with tumor 1, became moribund at much later time
points (mean 125 days, range 80–180 days) (Figure S6A).
Prkcb+/+ recipients showed a typical TCL1 phenotype, charac-
terized by massive splenomegaly, hepatomegaly, lymphade-
nopathy, and clonal expansion of CD5+ B cells (Figures 6C and
S6B). Histopathology showed a widespread lymphoma infiltra-
tion in lymphatic and extralymphatic tissues. Immunohistochem-
istry confirmed that these tumors were CD19+CD5+ B cell
lymphomas with a proliferation index (Mib-1+) of 5%–10% (Fig-
ure 6D). Strikingly, necrobiopsy revealed that none of the
Prkcb/ recipient mice developed a CLL-like disease (Fig-
ure 6C), and spleen and lymph nodes appearedmacroscopically
normal. The few mice that were transplanted with tumor 1 and
died showed large tumors in the peritoneal cavity. Single cells
from these tumors lacked surface expression of lymphoid
markers (data not shown). The presence of TCL1+CD19+CD5+
lymphocytes was assessed from spleens of Prkcb/ and wild-
type recipients at the time of sacrifice. Increased levels of
CD19+CD5+ lymphocytes were only detectable in wild-type
recipient mice, but not in Prkcb/ animals (Figure S6C). Histo-
pathology demonstrated that all tumors grown in Prkcb/
mice were histiocytic soft tissue sarcomas (Figure S6D,
a and b). Microscopically, sarcomas could also be detected in
the spleen of some Prkcb+/+ recipient mice transplanted from
the same primary tumor (Figure S6D, c and d).
To test whether CD5+ lymphocytes from diseased TCL1tg
micewere capable of inducing PKC-bII in BMSCs, we cocultured
TCL1+CD19+CD5+ lymphocytes on primary murine BMSCs
derived from wild-type, Prkcb/, and TCL1tg mice. Similar
to primary CLL cells from patients, TCL1+CD19+CD5+ cells
induced the expression of PKC-bII in wild-type and TCL1tg
BMSCs (Figure S6E), associated with improved ex vivo survival
(data not shown). Accordingly, NF-kBwas activated in mBMSCs
fromwild-typemice, but not inPrkcb/ stromal cells (Figure 6E).
These data indicate unambiguously that PKC-b induced and
expressed in the microenvironment is essential to establish a
CLL-like disease in vivo, whereas stromal PKC-b seems to be
dispensable for propagating soft tissue sarcomas.
To evaluate whether PKC-bII is upregulated in the microenvi-
ronment of patients with CLL, we assessed its expression in
stromal cells in bone marrow trephine biopsies. To overcome
the difficulties of a preponderance of malignant B cells that
express PKC-bII and the lack of reliable markers for most
stromal cells, we used CLL samples with a nodular, but not
diffuse, infiltration of the bone marrow, allowing analyzing
CLL-free and infiltrated sections in the same patient. In addition,
endothelial cells are a subpopulation of stromal cells that can be
reliably stained with an antibody against CD34 and can support
survival of monoclonal B cells dependent on the expression
of PKC-bII (Figures 2H, 2J, and 3G). Immunofluorescence ofeating stromal cells overnight with HTNC. After propagation of stromal cells for
fter contact with CLL cells for 5 days using EMSA (I). Accordingly, NEMO and
rmined by Annexin-V staining after 5 days (n = 10). Identically treatedmBMSCs
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Figure 5. NF-kB Upregulates the Expression of Cytokines and Adhesion Molecules, Crucial for CLL Survival on Stromal Cells
(A) Transcriptomes from NEMO-proficient (HTNC) BMSCs were compared to NEMO-deficient BMSCs (+HTNC) after 5 days of coculturing with primary CLL
cells (n = 7, individual patients are indicated by V numbers). Data were subjected to functional pathway analysis using the GeneTrail software package. Heatmaps
show two KEGG pathways exhibiting significant overrepresentation in the target list of consistently downregulated targets as determined bymicroarray analysis.
(B and C) Concentration of IL-1a (n = 9) and IL-15 (n = 15) was assessed in supernatants from NemoY/F-BMSC monocultures or from cocultures with CLL cells
after 5 days. Boxes depict 25th75th percentile; error bars indicate ±SEM of mean (line in the box). The Nemo gene is located on the X chromosome; therefore,
hemizygous male mice (Nemoy/F) correspond genetically to homozygous NemoF/F mice. ****p < 0.0001, ***p < 0.001, *p < 0.05.
(legend continued on next page)
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only expressed in endothelial cells in sections containing CLL
cell infiltrations (CD79a+), but not in those in CLL-free sections
(Figure 6F).
Upregulated Stromal PKC-bII Is a Recurrent Finding
in Hematological Malignancies
To test whether heterotypic interactions between BMSCs and
the tumor are also important for the survival and propagation
of other malignant cells, we cocultured primary human acute
lymphoblastic leukemia (ALL) cells and mantle cell lymphoma
(MCL) B cells for 5 days on EL08-1D2 cells. Although ALL cells
died at a significant higher rate than MCL cells in vitro, contact
with stromal cells reduced spontaneous apoptosis of both ALL
and MCL cells (Figure 7A). Similar to CLL cells, primary ALL
and MCL cells induced the expression of PKC-bII in EL08-1D2
cells (Figure 7B), suggesting that the PKC-bII/NF-kB pathway
is commonly activated in B cell malignancies. Indeed, we found
activated NF-kB in EL08-1D2 cells after coculture with ALL and
MCL cells, similar to coculture with CLL cells (Figure S7). The
importance of stromal PKC-bII for the survival of ALL and MCL
cells was confirmed by the support of survival of ALL and MCL
cells by the wild-type but not the Prkcb/ BMSCs (Figure 7C).
To evaluate whether PKC-bII was induced in stromal cells in vivo,
we analyzed human bone marrow trephine biopsies from
patients with a mature ALL and MCL for the expression of
PKC-bII in endothelial cells. Endothelial cells surrounded by
ALL and MCL cells expressed PKC-bII, whereas those outside
did not (Figure 7D). These data show that stromal PKC-bII is
upregulated in a variety of lymphoproliferative malignancies
and suggest that activation of the PKC-bII pathway could repre-
sent a general response of the tumor microenvironment to
support leukemogeneis/lymphomagenesis.
DISCUSSION
It has become more appreciated that tumors are not merely an
accumulation of monoclonal cells but rather are heterogeneous
complex structures, composed of malignant cells and various
host cells. This cancer-associated microenvironment contrib-
utes significantly to tumor progression by supplying prosurvival
factors crucial for the propagation of malignant cells. Therefore,
targeting the tumor microenvironment constitutes a treatment
option to bypass cancer cells’ intrinsic drug resistance.
Here, we report that the induction of PKC-bII in stromal cells is
required for the survival of leukemic B cells. Studies on PKC-b
knockout mice indicated that its function was restricted to
normal B cell physiology by linking the B cell receptor to
NF-kB activation (Leitges et al., 1996; Su et al., 2002). Reports
of PKC-b in the context of tumorigenesis are limited to intrinsic
high expression levels in B cell malignancies (Decouvelaere
et al., 2007) and the promotion of colon carcinogenesis through
a mechanism involving the accumulation of b-catenin (Fields
et al., 2009).(D and E) Increasing doses of murine IL-1a (D) and IL-15 (E) were supplemented to
5 days before the rate of apoptotic CLL cells was analyzed by Annexin-V/PI stai
Error bars show mean ± SEM.
See also Figure S5 and Tables S4 and S5.The induction of PKC-bII in the microenvironment by CLL
cells was neither species restricted nor limited to a subtype of
stromal cells. This suggests that CLL cells can communicate
with stromal cells through highly conserved and ubiquitously
expressed receptors, or the upregulation of PKC-bII is related
to metabolic alterations. The latter is supported by data showing
that a metabolic interplay between stromal cells and CLL cells
can promote survival of CLL cells (Zhang et al., 2012). Although
it is very reasonable to assume that the functional consequences
of PKC-bII activation differ between different subsets of stromal
cells, the induced expression of PKC-bII in all cell types marks its
potential as a therapeutic target. We observed that the expres-
sion of PKC-bII in endothelial cells in vivo was restricted to
vessels within the infiltrated bone marrow. Previously, activation
of PKC-bII in endothelial cells was observed as a response to
hypoxia in a nontumor mouse model and was required for
neovascularization (Suzuma et al., 2002). In this regard, the
expression of PKC-bII in endothelial cells may also be account-
able for the reported increase in bone marrow angiogenesis in
patients with CLL (Kini et al., 2000).
Our data demonstrate that PKC-bII, but not PKC-bI, is induced
in stromal cells activated by contact with monoclonal B cells.
This raises the important question of what upstream events
and signaling cascades are involved in the isoform-specific
regulation of PKC-b. PKC-b activity is modulated by the pres-
ence of lipid secondmessengers, calcium, and protein modifica-
tions, but little is known about the regulation of its protein level.
Quantification of PKC-b transcripts indicates that the increase
in PKC-bII protein is transcriptionally regulated. Importantly,
both isoforms are encoded by a single gene and arise via alter-
native splicing (Ono et al., 1987). This suggests that specific
stabilization of PKC-bII mRNA is accountable for an increase in
protein levels, similar to the regulation of PKC-b isoforms by
glucose (Patel et al., 1999) and insulin (Chalfant et al., 1995).
However, soluble factors were eliminated as the only determi-
nants to induce PKC-bII. It is important to mention that PKC-bII
protein was detectable by immunoblotting at the earliest
3 days after coculture with CLL cells (data not shown). This
delayed upregulation almost certainly excludes that PKC-bII is
a direct target gene engaged by an immediately activated
signaling pathway. Long-term cultures of hBMSCs and CLL cells
showed that PKC-bII levels steadily increased over time. This
ruled out that PKC-bII is subjected to a negative feedback loop
as reported for other PKC isoforms (Kang et al., 2000; Parker
et al., 1995) and is an important observation for the development
of PKC-b-directed therapies.
We show that NF-kB is linked through the canonical pathway
to PKC-bII in stromal cells, but Bcl10 is dispensable, demon-
strating that the mechanism by which PKC-bII activates NF-kB
in stromal cells is distinct from that utilized in normal B cells.
Alternative pathways linking PKC-b to NF-kB independently of
Bcl10 include the PKC-associated kinase (PKK) (Muto et al.,
2002) and Hsp27-mediated interaction with IKKb (Park et al.,
2003). Although, to our knowledge, the precise mechanism ofthe media of CLL monocultures or CLL/NEMO-deficient BMSC cocultures for
ning (n = 8). **p < 0.01; ns, statistically nonsignificant.
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Figure 6. Stromal PKC-b Is Indispensable for Establishing and Propagating CLL In Vivo
(A and B) A total of 23 107 splenic PBMCs from three diseased TCL1tgmicewas transplanted into syngeneic wild-type orPrkcb/ recipient mice (n = 18 for each
group: tumor 1 into eight Prkcb+/+ and eight Prkcb/mice; tumors 2 and 3 each in five recipient mice per genotype). The percentage of CD19+CD5+ B cells in the
blood of recipient micewas assessedweekly by flow cytometry (A). Mice in both cohorts were followed for signs of illness and killedwhenmoribund (B). Error bars
show mean ± SEM. ****p < 0.0001, ***p < 0.001.
(C) Necrobiopsy of Prkcb/ (n = 12) and wild-type recipient mice (n = 16). White arrows indicate organ infiltration with lymphoma cells.
(D) Immunohistochemistry of tumors that developed in wild-type recipient animals.
(legend continued on next page)
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Figure 7. Stromal PKC-bII Is Expressed in
Lymphoproliferative Diseases
(A and B) Primary malignant lymphocytes from the
blood of patients with ALL (n = 9) and MCL (n = 5)
were cultured in medium or cocultured on EL08-
1D2 cells for 5 days. Apoptotic B cells were
quantified by Annexin-V/PI staining (A), and the
expression of PKC-bII in EL08-1D2 cells was
analyzed by immunoblotting (B). Patients’ ID were
encrypted by A or M numbers.
(C) Primary B cells from three patients with
MCL and four patients with ALL were cultured in
medium or cocultured on confluent wild-type or
Prkcb/ BMSCs for 5 days. Apoptotic cells were
detected by flow cytometry and Annexin-V/PI
positivity. Patients’ ID were encrypted by A or M
numbers.
(D) Representative images of endothelial cells
(CD34+, white arrowheads) in bone marrow sec-
tions from ten patients with a mature form of ALL
and ten with MCL, analyzed for the expression of
PKC-bII. Infiltrated areas (a and c, CD79+) were
compared to noninfiltrated areas of the bone
marrow (b and d).
See also Figure S7.
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PKC-bII operates upstream of canonical NF-kB activation and
that its expression is a prerequisite to activate NF-kB in stromal
cells.
We have identified that stromal NF-kB regulates the expres-
sion of cytokines and of adhesion molecules. CLL cells can
bind to ICAM1 expressed on stromal cells via aLb2 integrins.
Therefore, the reduced expression of Icam1 in NEMO-deficient
cells suggests that impaired survival of CLL cells on these
stromal cells could also be related to reduced binding. Con-
versely NF-kB may support the survival of leukemic B cells
through enforced expression of adhesion molecules. Surpris-
ingly, we found genes generally known to play an important
role for the interaction between B and T cells expressed in
NEMO-proficient BMSCs after contact with CLL cells. Impor-(E) NF-kB activity was assessed by EMSA on nuclear extracts from TCL1tg,Prkcb+/+, andPrkcb/BMSCs, cu
cells harvested from a diseased TCL1tg mouse (n = 3).
(F) Representative images of human bone marrow trephine biopsies from 13 patients with CLL, analyzed
(CD34+, white arrowheads) in CLL-infiltrated areas (a, CD79a+) and outside the CLL-infiltrated bone marrow
See also Figure S6.
Cancer Cell 23, 77–9tantly, primary murine BMSCs are a
heterogeneous cell population, con-
stituted of nonhematopoietic cells and
antigen-presenting cells (APCs). De-
creased expression of CD86 in NEMO-
deficient BMSCs may therefore reflect
an exquisite dependence of APCs on
functional NF-kB. In addition, some of
these antigens, such as CD28, can also
be expressed in nonlymphoid stromal
cells (Gray Parkin et al., 2002). In addition
to adhesion molecules, NEMO regulated
the production and secretion of proin-
flammatory cytokines. As a proof ofprinciple, we have demonstrated that IL-1 and IL-15 can rescue
leukemic B cells from cell death. However, we assume that
in vivo, numerous cytokines in collaboration with enhanced
expression of adhesion molecules on the surface of stromal cells
stimulate CLL cells in parallel and presumably act synergistically
on malignant B cells to block apoptosis.
The observation that expression of PKC-bII in the microenvi-
ronment is essential to promote the survival of CLL cells provides
a reason to target PKC-bII therapeutically. Motivated by the
observation that specific PKC isoforms are intrinsically overex-
pressed in numerous different tumors, several PKC inhibitors
have already been developed. Enzastaurin, an orally available
PKC-b inhibitor, demonstrated clinical activity in a phase II trial
on patients with lymphoma with negligible toxicity (Robertson
et al., 2007). Numerous clinical studies are currently exploringltured in the absence or presence of CD19+CD5+B
for the expression of PKC-bII in endothelial cells
(b).
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variety of solid and hematopoietic malignancies (listed on
http://clinicaltrials.gov).
Based on our data, we propose a dual function of PKC-bII in
the pathogenesis of CLL: intrinsic expression and activation of
PKC-bII in CLL cells augment PKB/AKT signaling leading to
apoptosis resistance (Barraga´n et al., 2006), whereas its induc-
tion in stromal cells mediates microenvironment-dependent
survival. The crucial role of PKC-b for the pathogenesis of CLL
was recently demonstrated by crossing TCL1tg mice with
Prkcb/ mice (Holler et al., 2009). However, this experiment
does not allow deciphering the relative contribution of PKC-b
expressed in CD19+CD5+monoclonal B cells and in stromal cells
to the development of the disease.
The recently reported activation of NF-kB in CAFs from
mammary and pancreatic adenocarcinomas (Erez et al., 2010)
suggests that stromal PKC-bII could also operate upstream of
NF-kB in other tumor-associated stromal cells. This hypothesis
is further supported by the finding of overexpressed PKC-b in
stromal cells of human basal cell carcinomas (Reynolds et al.,
1997). Therefore, induced expression of PKC-b may be
a common mechanism of malignant cells to harness stromal
cells for tumor-promoting purposes. Therapeutic strategies aim-
ing at tumor cell intrinsic oncogenic pathways have been limited
in their success due to the genetic instability of tumor cells and
the evolution of mutations conferring drug resistance. In con-
trast, cancer-associated stromal cells presumably lack these
escape mechanisms and may therefore constitute an alternative
therapeutic target. Further studies are needed to explore
whether inhibition of PKC-b, expressed in tumor-associated
stromal cells, displays clinical significance.
EXPERIMENTAL PROCEDURES
Human and Mouse Samples
After informed patients’ consent and in accordance with the Helsinki declara-
tion, peripheral blood was obtained from untreated patients with a diagnosis of
CLL, ALL, and MCL. hBMSCs were collected from individuals who underwent
bone marrow aspiration for diagnostic purposes and in whom subsequently
a hematological disease was ruled out. Our studies on CLL, MCL cells, and
hBMSCs were approved for ex vivo experiments by the local ethical
committee of the Technical University Munich (project number 1894/07). The
collection and use of primary ALL and normal blood samples were approved
for ex vivo experiments by the local ethic committee of the University Hospital
of Essen (project numbers 10-4380 and 04-2459). Monoclonal B cells from
patients with MCL and ALL were isolated from peripheral blood at the time
of first diagnosis. PBMCs were isolated from heparinized blood or bone
marrow samples by centrifugation over a Ficoll-Hypaque layer (Biochrom,
Berlin) of 1.077 g/ml density. T cells and monocytes were removed with anti-
CD2 and anti-CD14 magnetic beads (Dynabeads M450; Dynal, Oslo). A total
of 2 3 104 BM-mononuclear cells was plated in 24-well tissue plates using
the media conditions described in the Supplemental Information. Adhering
cells were propagated at least for 3 weeks before experiments were per-
formed. mBMSCs were established from femora and tibiae of 4- to 8-week-
old mice accordingly. Each mouse provided about 53 107 bone marrow cells.
Syngeneic Transplantation of TCL1-CLL
As previously described by Hofbauer et al. (2011), a massively enlarged spleen
was removed from an aged and moribund Em-Tcl1tg mouse (provided by
C. Croce, Columbus, Ohio, USA), and single cells were obtained by homoge-
nizing the tissue and filtering cells through a 100 mm nylon cell strainer (BD
Falcon, Heidelberg, Germany). After separation of PBMCs by centrifugation
over a Ficoll-Hypaque layer, 20 3 106 cells were injected intraperitoneally90 Cancer Cell 23, 77–92, January 14, 2013 ª2013 Elsevier Inc.into 6- to 8-week-old syngeneic Prkcb+/+ or Prkcb/ mice. Experiments
were performed under approval from the Austrian Animal Ethics Committee.
Mice were housed in a specific pathogen-free facility and followed for signs
of illness. Moribund mice were killed and samples for histology and flow
cytometric analysis collected.
Statistical Analysis
Statistical analyses of the results were performed by one-way ANOVA followed
by Student’s t test. Throughout the manuscript, statistical significance
was defined as p < 0.0001 (****), p < 0.001 (***), p < 0.01 (**), p < 0.05 (*), or
ns (statistically nonsignificant).
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